[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"waist-circumference\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:waist-circumference":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":38,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100578896","how-a-mediterranean-diet-with-potatoes-impacts-heart-and-metabolic-health-in-adults-with-pre-diabetes-100578896",false,"NCT06817252","How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes","Effects of a Mediterranean Dietary Pattern With White Potato on Cardiometabolic Health in Adults With Pre-Diabetes","MEDPOT-PREDM","Inclusion Criteria:\n\n* Men and postmenopausal women within the Las Vegas\u002FHenderson NV area\n* Ages 45-80 years\n* BMI between 25-40 kg\u002Fm2\n* HbA1c between 5.7-6.4%\n* Individuals from different demographic backgrounds (i.e., American Indian or Alaska Native, Caucasians, Asian, Black or African-American, Native Hawaiian, Hispanic, Latino or Pacific Islander)\n* Individuals who are considered \"non-frequent\" white potato consumers (\\\u003C2 servings of baked potatoes\u002Fweek)\n* Individuals from all races, genders, sexual identities, and religions will be included\n* Individuals must follow certain guidelines, including avoiding new medications during the study or significant changes to lifestyle factors (e.g. beginning to smoke or exercise more or less than usual)\n\nExclusion Criteria:\n\n* Individuals with uncontrolled hypertension (≥160\u002F100mmHg), active cancer, asthma, thyroid, kidney, liver, or pancreatic diseases\n* Individuals who are currently using insulin, on dialysis, changing\u002Fadding hypoglycemic, anti-hypertensive, and hypocholesterolemic medication within ≤3 months (or throughout the study)\n* Individuals participating in weight loss programs or another clinical trial\n* Individuals who start smoking\n* Individuals who have unstable metabolic or chronic diseases\n* Individuals who may have allergies to potatoes\n* Woman who are currently pregnant, think they may be pregnant, or who is nursing cannot participate (women must be postmenopausal)","ALL","45 Years","80 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to is to determine the effects of baked potato with the skin (BP) + nutrition education focused on adherence for a Mediterranean Dietary Pattern (MEDNE) on glycemic control, cardiometabolic health, and dietary quality in individuals with pre-diabetes from different demographic backgrounds. The main questions it aims to answer are:\n\n* Does BP+MEDNE contribute to improvements in indices of glycemic control, vascular function, blood lipids, inflammation\u002Foxidative stress, and body composition?\n* Does BP+MEDNE contribute to improvements to overall dietary intake and quality?\n\nResearchers will compare BP+MEDNE to MEDNE alone to see if BP+MEDNE can improve glycemic control, cardiometabolic health, and dietary quality in individuals with pre-diabetes from different demographic backgrounds.\n\nParticipants will:\n\n* Be asked to come to the study site initially for a Screening Study Visit to confirm eligibility.\n* Be asked to come the study site for a Pre-Baseline and Pre-12-Week Study Visit (one week prior to Baseline and 12-Week Study Visits) for placement of placement of a continuous glucose monitor and wearable devices to be removed at Baseline and 12-Week Study Visits.\n* Be asked to come to the study site for Baseline, 6- and 12-Week Study Visits for assessments of glycemic control and cardiometabolic health.\n* Be asked to complete 3-Day Food Records throughout the 12 week study period for assessment of dietary quality (5 total)\n* Receive pre-recorded MEDNE ( which can be accessed via computer device\u002Fipad\u002Fsmartphone) after Baseline and 6-Week Study Visits.\n* If randomized to the BP+MEDNE group, participants will receive pre-prepared baked potatoes with the skin for the 12-week study period (every 3 weeks) at Baseline and 6-Week Study Visits and asked to come to the study site for picking up the pre-prepared baked potatoes at weeks 3 and 9 of the study period.",[28,29,30,31,32,33,34,35,36,37],"Prediabetes","Lipid Profile","Hypertension","Glycemic Control","Arterial Stiffness, Blood Pressure","Inflammation Biomarkers","Dietary Quality","Body Composition Measurement","Waist Circumference","Anthropometrics: Height and Weight",[39,28,40,41,34],"White Potato","Mediterranean Diet","Cardiometabolic Health","RECRUITING","2025-11-17",{"date":45,"type":46},"2025-11-20","ACTUAL",{"date":48,"type":46},"2025-04-24",{"date":50,"type":22},"2026-12-31",{"name":52,"class":53},"University of Nevada, Las Vegas","OTHER",2,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100488792","phase-4-effect-of-erugliflozin-on-liver-fat-liver-fibrosis-and-glycemic-control-in-type-ii-dm-patients-with-nashnafld-100488792","NCT05644717","Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH\u002FNAFLD","Effects of Ertugliflozin on Liver Fat, Liver Fibrosis & Glycemic Control in Subjects With Type 2 Diabetes Mellitus (T2DM) & Non-Alcoholic Fatty Liver Disease \u002FNon-Alcoholic Steatohepatitis","Ertu-NASH","Inclusion Criteria:\n\n* Patient able to provide written informed consent\n* Adult males \\& females between 18 to 65 years\n* SGLT2i and insulin naïve patients\n* BMI \\>23 Kg\u002Fm2\n* HbA1C % ≥ 6.5 to 10\n* Documented hepatic steatosis or fatty liver disease on Ultrasound\n* Patient with Type II Diabetes Mellitus\n\nExclusion Criteria:\n\n* History of use of SGLT 2 inhibitors or Glucagon-like peptide (GLP) 1 agonist or insulin; 3 months prior to enrollment in the study.\n* Pioglitazone use in the past 6 months\n* History of vitamin E use (400mg twice daily) 3 months prior to enrollment in the study.\n* History of anti-obesity medication or weight loss procedure (bariatric surgery) use within 3 months prior to enrollment in the study.\n* History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requires frequent dose adjustment, or Cushing's syndrome)\n* History of liver disease including viral hepatitis, auto-immune hepatitis, liver cirrhosis, hepatocellular carcinoma and\u002For HIV\n* History of recurrent UTIs and mycotic infection.\n* Severely ill patients (who have high grade fever, sepsis or acute infection)\n* Pregnant woman, lactating woman or planning pregnancy during study duration\n* History of Drug-induced liver disease (e.g. amiodarone, valproate, tamoxifen, methotrexate, steroids (including homeopathic medicines).\n* History of active substance abuse (cannabinoid-derived substances like heroin, cocaine, amphetamines) based on history and\u002For laboratory tests\n* Alcohol intake 10 - 30 g\u002Fday (three drinks per day) within the previous year\n* Active substance abuse such as acetaminophen over-use, hashish, tobacco products, heroin, cocaine or amphetamines.\n* Severe hepatic impairment ( AST \\& ALT levels \\> 3 times upper limit normal","18 Years","65 Years",{"count":66,"type":22},164,[68],"PHASE4","Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \\& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)\u002FNon-Alcoholic Steatohepatitis (NASH)",[71,72,31,73,36,74],"Liver Fat","Liver Fibrosis","Body Weight Changes","Tolerance","2025-03-19",{"date":77,"type":46},"2025-03-21",{"date":79,"type":46},"2023-03-01",{"date":81,"type":22},"2025-12-01",{"name":83,"class":84},"Getz Pharma","INDUSTRY",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":17,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":105,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":85},"100575957","clinical-profile-of-skin-aging-based-on-dermoscopy-photoaging-scale-and-glogau-scale---study-of-leucocyte-telomere-length-biomarker-p16-and-body-mass-index-100575957","NCT06779032","Clinical Profile of Skin Aging Based on Dermoscopy Photoaging Scale and Glogau Scale - Study of Leucocyte Telomere Length, Biomarker P16, and Body Mass Index","LTLP16","Inclusion Criteria:\n\n* female aged 31-61 years\n* healthy\n* willing to participate in the study\n\nExclusion Criteria:\n\n* history of diseases (heart, kidney, liver)\n* pregnant or breastfeeding patientes",true,"31 Years","61 Years",{"count":97,"type":22},70,"OBSERVATIONAL","To determine the relationship between clinical appearance, dermoscopic examination results of photoaging profiles based on clinical examination, DPAS score and leucocyte telomere length, to analyze the relationship between BMI, waist circumference, triglycerides, and cellular senescence biomarker p16 levels with a population experiencing skin aging and having Fitzpatrick III-V skin types.\n\nThe questions which is aim to be answered are:\n\n1. What is the photoaging profile based on clinical examination results in skin aging cases?\n2. What is the photoaging profile based on DPAS scores in skin aging cases?\n3. What is the leucocyte telomere length profile in skin aging cases?\n4. What is the relationship between leucocyte telomere length and clinical examination in skin aging cases?\n5. What is the relationship between leucocyte telomere length and DPAS degree in skin aging cases?\n6. What is the profile of cellular senescence p16 biomarker levels in a population that has experienced clinical skin aging with Fitzpatrick III-V skin types?\n7. What is the skin aging profile based on the Glogau and DPAS scales in a population with Fitzpatrick III-V skin types?\n8. Is there a relationship between the results of the cellular senescence p16 biomarker examination and clinical skin aging assessed based on the Glogau and DPAS scales in a population with Fitzpatrick III-V skin types?\n9. Is there a relationship between the results of BMI, waist circumference, and triglyceride examinations with clinical skin aging assessed using the Glogau and DPAS scales with Fitzpatrick III-V skin types?",[101,102,103,104,36],"Aging Skin","Body Mass Index","Cellular Senescence","Triglycerides",[106,107,108,109,110,111],"skin aging","body mass index","triglycerides","waist circumference","cellular senescene","p16","NOT_YET_RECRUITING","2025-01-12",{"date":115,"type":46},"2025-01-16",{"date":117,"type":22},"2025-02-05",{"date":119,"type":22},"2025-08-20",{"name":121,"class":53},"Indonesia University"]